The angiotensin receptor–neprilysin inhibitor (ARNI), sacubitril/valsartan, confers additional protective effects compared with angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEIs/ARBs) in terms of reversed left ventricular (LV) remodelling and improves the prognosis of patients with heart failure (HF). However, few studies have examined the effects of ARNI on the left atrium. Accordingly, this study compared the effects of ARNI and ACEI/ARB on left atrial (LA) remodelling in heart failure with reduced ejection fraction (HFrEF).

中文翻译：

---

血管紧张素受体脑啡肽酶抑制剂对心力衰竭左心房重构及预后的影响

与血管紧张素转换酶抑制剂/血管紧张素 II 受体阻滞剂 (ACEIs/ARB) 相比，血管紧张素受体-脑啡肽酶抑制剂 (ARNI) 沙库巴曲/缬沙坦在逆转左心室 (LV) 重塑方面具有额外的保护作用，并改善了患者的预后。心力衰竭（HF）患者。然而，很少有研究检查 ARNI 对左心房的影响。因此，本研究比较了 ARNI 和 ACEI/ARB 对射血分数降低 (HFrEF) 心力衰竭左心房 (LA) 重塑的影响。